Match!

CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors

Published on Dec 1, 2017in Annals of Translational Medicine
· DOI :10.21037/17577
Emilie Mamessier20
Estimated H-index: 20
,
David J. Birnbaum9
Estimated H-index: 9
+ 2 AuthorsFrançois Bertucci52
Estimated H-index: 52
Abstract
In the early 1990s, the team of Dr. Honjo identified a new gene that was upregulated during T-cell activation, supposedly as an apoptosis-associated molecule (1). This gene was named programmed cell death-1 ( PD-1 or CD279 or PDCD1 ). The PD-1 protein turned out to be a receptor delivering a co-inhibitory signal, playing a decisive role in maintaining peripheral tolerance and impeding autoimmunity, but with no effect on cell apoptosis. In 2000, Drs. Freeman and Sharpe discovered the natural ligands for the PD-1 receptor, called programmed cell death-1 ligand-1 (PD-L1 or CD274 or PDCD1L1) and programmed cell death-1 ligand-2 (PD-L2 or CD273 or PDCD1L2) (2,3).
  • References (0)
  • Citations (1)
📖 Papers frequently viewed together
20144.02Apoptosis
14 Citations
6 Authors (Soo-Yeon Park, ..., Ho-Geun Yoon)
17 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References0
Newest
Cited By1
Newest
#1Lei Chen (WHU: Wuhan University)H-Index: 5
#2Qi-Chao Yang (WHU: Wuhan University)H-Index: 1
Last. Zhi-Jun Sun (WHU: Wuhan University)H-Index: 33
view all 10 authors...
CMTM6, a regulator of PD-L1 expression, also modulates tumor immunity. Little is known about the function of CMTM6 and its mechanism of action in head and neck squamous cell carcinoma (HNSCC). In this study, we found by immunohistochemistry (IHC) analysis that CMTM6 overexpression predicted a poor prognosis for HNSCC patients. We discovered that CMTM6 expression was correlated with increased activity through the Wnt/β-catenin signaling pathway, which is essential for tumorigenesis, maintenance o...
3 CitationsSource
#2Pascal Finetti (AMU: Aix-Marseille University)H-Index: 43
Last. François Bertucci (AMU: Aix-Marseille University)H-Index: 32
view all 7 authors...
ABSTRACTAdrenocortical carcinomas (ACCs) are heterogeneous cancers associated with a very poor prognosis. The improvement of prognostic tools and systemic therapy are urgently needed. Targeting the...
Source
#1Jon Zugazagoitia (Yale University)H-Index: 1
#2Yuting Liu (Yale University)H-Index: 3
Last. David L. Rimm (Yale University)H-Index: 81
view all 11 authors...
Abstract Introduction CMTM6 has been described as a PD-L1 regulator at the protein level by modulating stability via ubiquitination. In this study, we describe the patterns of CMTM6 expression and assess its association with response to PD-1 pathway blockade in non-small-cell lung cancer (NSCLC). Methods We used multiplexed quantitative immunofluorescence to determine the expression of CMTM6 and PD-L1 in 438 NSCLCs represented in tissue microarrays, including two independent retrospective cohort...
Source
#1Young Wha Koh (Ajou University)H-Index: 8
#2Jae Ho Han (Ajou University)H-Index: 22
Last. Hyun Woo Lee (Ajou University)H-Index: 73
view all 5 authors...
ABSTRACTCKLF-like MARVEL transmembrane domain containing 6 (CMTM6) plays a crucial role in the stability of the programmed death-ligand 1 (PD-L1). However, there has been no previous study of CMTM6...
Source
#1Peixin Dong (Hokkaido University)H-Index: 18
#2Ying Xiong (SYSU: Sun Yat-sen University)H-Index: 13
Last. Hidemichi Watari (Hokkaido University)H-Index: 28
view all 5 authors...
Although the role of PD-L1 in suppressing the anti-tumor immune response is extensively documented, recent discoveries indicate a distinct tumor-intrinsic role for PD-L1 in modulating epithelial-to-mesenchymal transition (EMT), cancer stem cell (CSC)-like phenotype, metastasis and resistance to therapy. In this review, we will focus on the newly discovered functions of PD-L1 in the regulation of cancer development, describe underlying molecular mechanisms responsible for PD-L1 upregulation and d...
15 CitationsSource